Liminatus Pharma, Inc. issued warrants to purchase an aggregate of up to 20,688,000 shares of common stock of warrant to a holder (the "Holder") of its existing common stock warrants for aggregate gross proceeds from the exercise of the Existing Warrants is approximately $1,861,920.00.
“Warrants” and, together with the New Black-Scholes Warrants, the “Inducement Warrants”). The aggregate gross proceeds from the exercise of the Existing Warrants is approximately $1,861,920.00, before deducting financial advisory fees. The Company intends to use the net proceeds from the exercise of the Existing Warrants for working capital and general corporate”
Material Agreements
Liminatus Pharma, Inc. entered into Inducement Letter Agreement with a holder of its existing common stock warrants valued at $1,861,920.00 (effective 2026-06-03).
“On June 3, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter Agreement”) with a holder (the “Holder”) of its existing common stock warrants”
Listing & Compliance Notices
Liminatus Pharma, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).
“May 20, 2026, the Company received a notice from Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will be delisted from The Nasdaq Global Mark”
Material Agreements
Liminatus Pharma, Inc. entered into Merger Agreement with InnocsAI LLC valued at 1,600,000,000 shares of the Company’s common stock, at an issue price of $0.20 per share (effective 2026-05-17).
“On May 17, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a Merger Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”) with InnocsAI LLC, Delaware limited liability company (“InnocsAI”), and NamChul Jung, an individual, as the representative of the members of InnocsAI.”
Governance Changes
Liminatus Pharma, Inc.: Reduced stockholder meeting quorum requirement from majority to one-third of voting power (effective 2026-02-27).
“On February 27, 2026, the Board of Directors (the “Board”) of Liminatus Pharma, Inc. (the “Company”) approved an amendment to the Company’s bylaws (the “Bylaws”) to reduce the quorum requirement for meetings of the stockholders from a majority to one-third (1/3) of the voting power of the capital stock of the Company issued and outstanding and entitled to vote (the “Bylaw Amendment”).”
Material Agreements
Liminatus Pharma, Inc. entered into Purchase Agreement with certain purchasers party thereto (effective 2026-02-17).
“the Company entered into a securities purchase agreement (the "Purchase Agreement") with certain purchasers party thereto.”
Equity Issuances
Liminatus Pharma, Inc. issued 4,000,000 shares of common stock to Clear Street LLC for surrender and cancellation of 805,377 warrants.
“On February 6, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a settlement and release agreement (the “Settlement Agreement”) with Clear Street LLC (the “Holder”), pursuant to which the Company agreed to issue 4,000,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), to the Holder in exchange for the surrender and cancellation of 805,377 warrants (the “Warrants”) to purchase shares of Common Stock held by the Holder.”
Material Agreements
Liminatus Pharma, Inc. entered into Settlement Agreement with Clear Street LLC (effective 2026-02-06).
“On February 6, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a settlement and release agreement (the “Settlement Agreement”) with Clear Street LLC (the “Holder”), pursuant to which the Company agreed to issue 4,000,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), to the Holder in exchange for the surrender and cancellation of 805,377 warrants (the “Warrants”) to purchase shares of Common Stock held by the Holder.”
Listing & Compliance Notices
Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“January 15, 2026, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”) which requires listed securities to maintain a minimum bid price of $1 per share. The notification has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on Nasdaq under the symbol “”
Listing & Compliance Notices
Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).
“November 19, 2025, Liminatus Pharma, Inc. (the “Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value of Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of the Company’s MVLS for the last 30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 (”
Listing & Compliance Notices
Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“August 22, 2025, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”). The deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on Nasdaq under the symbol “LIMN” at this time. Under the Nasdaq rules, the Company has 60 calendar da”
Listing & Compliance Notices
Liminatus Pharma, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).
“May 29, 2025, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Form 10-Q”). On June 2, 2025, the Company filed the Form 10-Q with the U.S. Securities and Exchange Commission. On June 3, 2025, the Company received a letter from the Staff stating that the Company had regained compli”
Governance Changes
Liminatus Pharma, Inc.: Iris ceased being a shell company as a result of the business combination.
“As a result of the Business Combination, Iris ceased being a shell company.”
Governance Changes
Liminatus Pharma, Inc.: Approved and adopted a new Code of Ethics applicable to all employees, officers and directors in connection with the business combination (effective 2025-04-30).
“In connection with the Business Combination, on April 30, 2025, the Board approved and adopted a new Code of Ethics applicable to all employees, officers and directors of the Company”
Governance Changes
Liminatus Pharma, Inc.: Amended and restated certificate of incorporation to change corporate name to Liminatus Pharma, Inc., adjust authorized capital stock, and replace constitutional documents in connection with business combination (effective 2025-04-30).
“On April 30, 2025, in connection with the Business Combination, the Company filed the Charter with the Secretary of State of the State of Delaware, including the changing of the Company’s name to “Liminatus Pharma, Inc.,” and adopted the Bylaws”
M&A Transactions
Liminatus Pharma, Inc. underwent a change of control involving Iris Acquisition Corp for 17.5 million shares of ParentCo Common Stock (based on a deemed price of $10.00 per share) (closed 2025-04-30).
“on Form 8-K filed by Iris with the SEC on December 1, 2022. Completion of the Mergers As previously reported on the Current Report on Form 8-K filed by Iris with the SEC on March 10, 2025, Iris held a special meeting of stockholders on March 4, 2025 (the “Special Meeting”). At the Special Meeting, Iris’ stockholders approved the proposals outlined in the Proxy”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.